Guidelines for Combined Hormonal Contraception in Women ≥ 35 years

1. Smoking – the decisive contraindication

Combined estrogen‑progestin contraceptives (pills, patches, rings) are absolutely contraindicated in any woman ≥ 35 years who smokes, regardless of the number of cigarettes. 1
The relative risk of myocardial infarction rises to ≈ 12.5‑fold in smokers ≥ 35 years using combined contraception, especially when consumption exceeds 15–20 cigarettes per day. 3
This contraindication applies to all routes of administration (oral, transdermal patch, vaginal ring). 1
Even light smoking (< 15 cigarettes/day) does not make combined contraception acceptable; any smoking is a contraindication. 3
The majority of coronary and cerebrovascular events among contraceptive users occur in women aged 35‑40 years, with smoking being the principal contributor. 3

Combined hormonal contraception should be avoided when systolic/diastolic blood pressure is ≥ 140/90 mm Hg (or ≥ 160/100 mm Hg in severe cases). 1
Blood‑pressure measurement is the only mandatory clinical examination before prescribing combined contraception. 1
In women ≥ 35 years with hypertension, combined contraception is contraindicated irrespective of antihypertensive treatment status. 1
Hypertensive women using combined contraception have a markedly increased risk of stroke (odds ratio 3.1‑14.5) and myocardial infarction (odds ratio 6‑68). 5

Personal history of venous thromboembolism (deep‑vein thrombosis or pulmonary embolism). 6
Personal history of arterial events (stroke, transient ischemic attack, coronary heart disease). 1
Migraine with aura or a family history of premature cardiovascular events (< 50 years). 1
Documented thrombophilia (e.g., factor V Leiden, prothrombin mutation, protein C/S deficiency). 6
Diabetes with vascular complications (nephropathy, advanced retinopathy, neuropathy). 1

Progestin‑only contraceptives (pills, levonorgestrel IUD, etonogestrel implant, depot medroxyprogesterone acetate) do not increase cardiovascular or thrombotic risk and are safe regardless of age, smoking status, or controlled hypertension. 1
Progestin‑only pills show a relative risk of venous thromboembolism of 0.90 (95 % CI 0.57‑1.45), indicating no increased risk. 3
Levonorgestrel IUD provides > 99 % efficacy, carries no thrombosis risk, and reduces heavy menstrual bleeding. 3
Etonogestrel subdermal implant offers > 99 % efficacy without estrogen‑related cardiovascular risks. 3
Depot medroxyprogesterone acetate (DMPA) does not increase stroke risk, though requires careful follow‑up. 3
These progestin‑only methods remain safe even in the presence of uncontrolled hypertension (≥ 160/100 mm Hg), established cardiovascular disease, or active smoking. 5
Copper IUD provides > 99 % efficacy with no hormonal or cardiovascular risk, suitable for all women ≥ 35 years, including those with multiple cardiovascular risk factors. 3

No smoking (any amount). 1
Blood pressure < 140/90 mm Hg. 1
No personal or first‑degree family history of premature cardiovascular events. 1
No migraine with aura. 1
No diabetes, dyslipidemia, or thrombophilia. 1
No history of venous or arterial thromboembolism. 6

Low‑dose estrogen formulations (e.g., 20 µg ethinyl estradiol) are not safer; the same contraindications apply to all estrogen doses and routes. 3
Transdermal patches and vaginal rings are not safer alternatives for smokers or hypertensive women ≥ 35 years; they carry identical cardiovascular risks. 1
Do not delay switching to progestin‑only methods when smoking continues or hypertension develops. 3

Effective contraception should be continued until menopause or age 50‑55 years. 3
Pregnancy during perimenopause carries higher risks of hemorrhage, venous thromboembolism, maternal death, spontaneous abortion, stillbirth, and congenital anomalies. 3

Discontinue combined contraception immediately. 1
Offer a progestin‑only pill, levonorgestrel IUD, etonogestrel implant, or copper IUD. 3
Continue combined contraception with annual reassessment. 1
Monitor blood pressure at each visit. 1
Provide counseling on smoking cessation and cardiovascular risk reduction. 3